CLASS II Device recall · Reported 11 Apr 2018 · FDA Enforcement Report

Oncomine Dx Target Test User Guides and Assay Definition File recalled

Life Technologies is recalling Oncomine Dx Target Test User Guides and Assay Definition File, distributed in Arizona, California, North Carolina, Texas, Virginia. The recall was initiated on 4 Dec 2017 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot Numbers: v1.8 (Rev. C) (REVC20170906) and v1.8 (Rev. C) (REVC27JUN2017) UDI: (01)10190302006071
Quantity recalled9

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1279-2018
FDA event ID
79437
Recalling firm
Life Technologies, Frederick, MD
Classification
Class II
Status
Terminated
Recall initiated
4 Dec 2017
FDA classified
30 Mar 2018
Reported
11 Apr 2018
Type
Voluntary: Firm initiated
Customers notified by
E-Mail
Reason category
Potency & Assay

Timeline

4 Dec 2017Recall initiated by company
30 Mar 2018Classified by FDA+116 days
11 Apr 2018Published in enforcement report+12 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

The Oncomine Dx Target Test may report erroneous results when used off-label for samples other than non-small cell lung cancer (NSCLC) tumor specimens.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Oncomine Dx Target Test User Guides and Assay Definition File, Model: A32461; UDI: (01)10190302006071(11)170911(10)1.8(240)A32461 The Oncomine Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high- throughput, parallel-sequencing technology to detect single-nucleotide variants (SNVs) and deletions in 23 genes from DNA and fusions in ROS1 from RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from patients with non-small cell lung cancer (NSCLC) using the Ion PGM Dx System. The test is indicated to aid in selecting NSCLC patients for treatment with the targeted therapies listed in Table 1 in accordance with the approved therapeutic product labeling.

Where it was distributed

US Distribution to the states of: AZ, CA, NC, TX, and VA.

ArizonaCaliforniaNorth CarolinaTexasVirginia

Stores named: Target

Questions about this recall

Is Oncomine Dx Target Test User Guides and Assay Definition File recalled?

Yes. Life Technologies recalled Oncomine Dx Target Test User Guides and Assay Definition File on 4 Dec 2017. The recall is Class II and its status is Terminated. Recall number Z-1279-2018.

Why was it recalled?

The Oncomine Dx Target Test may report erroneous results when used off-label for samples other than non-small cell lung cancer (NSCLC) tumor specimens.

Which lots are affected?

Lot Numbers: v1.8 (Rev. C) (REVC20170906) and v1.8 (Rev. C) (REVC27JUN2017) UDI: (01)10190302006071

Where was it sold?

US Distribution to the states of: AZ, CA, NC, TX, and VA.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Life Technologies

All 23

Other Test Kits & Diagnostics recalls

All 2,656